Quick Answer
Werewolf Therapeutics, Inc. reported Net Income of -$60.82 million for fiscal year 2025.
Werewolf Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$60.82M +13.7% |
-$70.52M -88.7% |
-$37.37M +30.6% |
-$53.81M -7.7% |
-$49.98M -232.3% |
-$15.04M |
| Diluted EPS | -$1.33 +18.4% |
-$1.63 -55.2% |
-$1.05 +43.5% |
-$1.86 +83.0% |
-$10.94 +61.0% |
-$28.08 |
| Total Assets | $69.40M -45.3% |
$126.93M -27.4% |
$174.83M +9.1% |
$160.25M -10.6% |
$179.25M +85.9% |
$96.40M |
| Cash and Equivalents | $57.05M -48.6% |
$111.00M -17.4% |
$134.34M +3.9% |
$129.31M -17.9% |
$157.53M +70.2% |
$92.57M |
| Stockholders Equity | $24.80M -66.2% |
$73.39M -34.1% |
$111.37M -9.0% |
$122.34M -19.9% |
$152.79M +394.6% |
-$51.86M -113.4% |
| R&D Expense | $44.83M -20.6% |
$56.43M +35.1% |
$41.78M -22.3% |
$53.76M +52.4% |
$35.27M +111.9% |
$16.64M |
| Operating Income | -$60.68M +17.6% |
-$73.59M -81.7% |
-$40.50M +27.7% |
-$56.06M -11.9% |
-$50.09M -123.6% |
-$22.40M |
| Shares Outstanding | 48.60M +8.4% |
44.83M +14.6% |
39.11M +24.4% |
31.43M +15.1% |
27.31M +2206.8% |
1.18M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$16.37M | +1.8% | +9.0% |
| Diluted EPS | September 30, 2025 | -$0.36 | +5.3% | +10.0% |
| Total Assets | September 30, 2025 | $79.63M | -43.1% | -14.0% |
| Cash and Equivalents | September 30, 2025 | $65.71M | -46.5% | -15.3% |
| Stockholders Equity | September 30, 2025 | $29.61M | -66.9% | -28.6% |
| R&D Expense | September 30, 2025 | $11.63M | -7.1% | -11.5% |
| Operating Income | September 30, 2025 | -$15.73M | +8.2% | +10.4% |
| Shares Outstanding | September 30, 2025 | 47.27M | +8.1% | +4.3% |
- Werewolf Therapeutics, Inc. reported Net Income of -$60.82 million for fiscal year 2025.
- Werewolf Therapeutics, Inc. showed an increase of +13.7% in Net Income compared to the prior fiscal year.
- Werewolf Therapeutics, Inc. reported Diluted EPS of $1.33 per share (loss) for fiscal year 2025.
- Werewolf Therapeutics, Inc. showed an increase of +18.4% in Diluted EPS compared to the prior fiscal year.
- Werewolf Therapeutics, Inc. reported Total Assets of $69.40 million for fiscal year 2025.
- Werewolf Therapeutics, Inc. showed a decrease of -45.3% in Total Assets compared to the prior fiscal year.
- Werewolf Therapeutics, Inc. reported Cash and Equivalents of $57.05 million for fiscal year 2025.
- Werewolf Therapeutics, Inc. showed a decrease of -48.6% in Cash and Equivalents compared to the prior fiscal year.
- Werewolf Therapeutics, Inc. reported Stockholders Equity of $24.80 million for fiscal year 2025.
- Werewolf Therapeutics, Inc. showed a decrease of -66.2% in Stockholders Equity compared to the prior fiscal year.
- Werewolf Therapeutics, Inc. reported R&D Expense of $44.83 million for fiscal year 2025.
- Werewolf Therapeutics, Inc. showed a decrease of -20.6% in R&D Expense compared to the prior fiscal year.
- Werewolf Therapeutics, Inc. reported Operating Income of -$60.68 million for fiscal year 2025.
- Werewolf Therapeutics, Inc. showed an increase of +17.6% in Operating Income compared to the prior fiscal year.
- Werewolf Therapeutics, Inc. reported Shares Outstanding of 48.60 million shares for fiscal year 2025.
- Werewolf Therapeutics, Inc. showed an increase of +8.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: